Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.
$17.25 +0.33 (1.95%)
As of 04/09/2021 15:59:21 EST IEX book CBOE book
2021 © Stock Market MBA, Inc.